| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/31/2001 | WO2001037856A1 Urotensin-ii cyclic analogs |
| 05/31/2001 | WO2001037845A1 Treatment of heart rhythm disturbances with n6-substituted-5'-(n-substituted) carboxamidoadenosines |
| 05/31/2001 | WO2001037837A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001037836A1 Diimino-piperazine derivatives for use as modulators of cell regulation |
| 05/31/2001 | WO2001037835A1 Novel compounds |
| 05/31/2001 | WO2001037830A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | WO2001037824A1 Use of 5ht3 agonists for relaxing the fundus |
| 05/31/2001 | WO2001037823A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 05/31/2001 | WO2001037820A2 Ionizable indolinone derivatives and their use as ptk ligands |
| 05/31/2001 | WO2001037819A2 Use of indirubine derivatives for making medicines |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037780A2 Urotensin-ii analogs |
| 05/31/2001 | WO2001003683A3 Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts |
| 05/31/2001 | WO2000075172A3 Factor viia inhibitors |
| 05/31/2001 | WO2000073307A3 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 05/31/2001 | WO2000063222A3 Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000056350A3 Methods of use of beta 1-integrin inhibitors |
| 05/31/2001 | WO2000042071A3 Compounds and methods to inhibit or augment an inflammatory response |
| 05/31/2001 | WO2000009512A3 Bipyridine manganese complexes |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | US20010002391 Administering to the mammal for ischmeic treatment an effective amount of an necrosis factor(NF)- kappa B activation inhibitor selected from the group consisting of proteasome inhibitor, ubiquitin pathwaty inhibitors |
| 05/31/2001 | DE19957156A1 New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders |
| 05/31/2001 | DE19956791A1 New 2-heterocyclyl-4-arylsulfonyl-5-amino-oxazole derivatives useful in treatment of central nervous system disorders and as pesticides |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2395564A1 Novel compounds |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2392576A1 .beta.-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392369A1 Treatment of heart rhythm disturbances with n6-substituted-5'-(n-substituted) carboxamidoadenosines |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392355A1 Oxidized apolipoproteins and methods of use |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2392149A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | CA2391386A1 Peptides having antiangiogenic activity |
| 05/31/2001 | CA2391012A1 Pyrazinone thrombin inhibitors |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2390465A1 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2389679A1 Novel sulfonyloxazolamines |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/31/2001 | CA2386955A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/31/2001 | CA2386893A1 N-alkylated peptides having antiangiogenic activity |
| 05/30/2001 | EP1103607A1 Enhancement of tmTNF levels for the sensitisation of tumours to sTNF and/or cytostatic drugs |
| 05/30/2001 | EP1103544A2 Piperidine derivatives and antiplatelet agents containing the same |
| 05/30/2001 | EP1103272A2 Modulation of TGF-beta by proteolytic enzymes |
| 05/30/2001 | EP1102842A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/30/2001 | EP1102769A2 Tricyclic carboxamides |
| 05/30/2001 | EP1102768A1 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 05/30/2001 | EP1102767A1 Substituted pyrazole derivatives |
| 05/30/2001 | EP1102766A1 Triazolopyridines for the treatment of thrombosis disorders |
| 05/30/2001 | EP1102762A2 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 05/30/2001 | EP1102761A2 Cyclopentabenzofuran derivatives and their use |
| 05/30/2001 | EP1102757A1 Substituted oxazole and thiazole derivatives as hppar gamma and hppar alpha activators |
| 05/30/2001 | EP1102750A1 Amide derivatives useful as inhibitors of the production of cytokines |
| 05/30/2001 | EP1102746A1 Substituted phenylamidines with antithrombotic action |
| 05/30/2001 | EP1102745A1 A process for the preparation of zofenopril calcium salt |
| 05/30/2001 | EP1102743A1 Amide derivatives which are useful as cytokine inhibitors |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102587A2 Vitronectin receptor antagonists |
| 05/30/2001 | EP1102585A2 USE OF CYCLOPENTABENZOFURAN-DERIVATIVES FOR COMBATING NF-$g(k)B-DEPENDENT DISEASES |
| 05/30/2001 | EP1102584A2 Antioxidant, antiproliferous composition, comprising a carnitine and a carotenoid |
| 05/30/2001 | EP1102567A1 Cardiac disease treatment device and method |
| 05/30/2001 | EP1102535A2 Compounds and methods |
| 05/30/2001 | EP0752992B1 IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 05/30/2001 | CN1297454A Novel omega-conotoxin peptides |
| 05/30/2001 | CN1297440A Piperidinyl and N-amidinopiperidinyl derivs. |
| 05/30/2001 | CN1297436A Substd. pyrrolidine hydroxamate metalloprotease inhibitors |
| 05/30/2001 | CN1297432A Substd. amides, their production and their use |
| 05/30/2001 | CN1297351A Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 05/30/2001 | CN1296841A Extract of Chinese-medicinal herbs and its application |
| 05/30/2001 | CN1296785A Beverage for altitude anoxia |
| 05/30/2001 | CN1066445C Aroyl-piperidine derivs. |
| 05/30/2001 | CN1066441C Isooxazolyl phenyl sulfonamide derivs. and use of same in preparing endothelin antagonists |
| 05/29/2001 | US6239288 Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis |
| 05/29/2001 | US6239267 Nucleotide sequence of ion channel protein associated with capsaicin; diagnosis and treatment of nervous system disorders, incontinence, stroke; antiischemic agents; antiarthritic/antiinflammatory agents; analgesics |
| 05/29/2001 | US6239172 Mixture of angiogenic growth factor and l-arginine; brain and cardiovascular disorders |
| 05/29/2001 | US6239156 Reduction of glutamate neurotoxicity by the administration of the neuroprotectant riluzole, |
| 05/29/2001 | US6239151 Compounds as inhibitor of tumor necrosis factor alpha release |
| 05/29/2001 | US6239147 To treat cns, gastrointestinal and other disorders. substance p antagonists having improved activity and fewer side effects, treatment of emesis induced by antineoplastic agents, isochroman ring |
| 05/29/2001 | US6239138 Vitronectin receptor antagonist |
| 05/29/2001 | US6239135 Arylpiperazines having activity at the serotonin 1A receptor |
| 05/29/2001 | US6239132 Thrombin inhibitors |
| 05/29/2001 | US6239128 Combating diseases and disorders associated with or mediated by the release of excitatory amino acids, associated with reduced blood flow to the brain and other cns tissue, |
| 05/29/2001 | US6239121 4- Halogenated steroids, preparation method and intermediates, application as medicines and pharmaceutical compositions containing same |
| 05/29/2001 | US6238921 Antisense oligonucleotide modulation of human mdm2 expression |
| 05/29/2001 | US6238883 Neurotransmitter transporter SC6 |
| 05/29/2001 | US6238878 FVlla/TF activity inhibiting compounds |
| 05/29/2001 | US6238872 Inhibiting restenosis by inserting stent that has antigen attached, then administering antibody labeled with radioactive source; immunotherapy |
| 05/29/2001 | US6238665 Anti-edema agent |
| 05/29/2001 | CA2091506C Thieno[3,2-b]pyridine derivatives |
| 05/29/2001 | CA2065292C Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction |
| 05/25/2001 | WO2001036979A2 Placental human neurokinin b precursor |
| 05/25/2001 | WO2001036642A1 HUMAN MONOCLONAL ANTIBODIES AGAINST TGF-βII RECEPTOR AND MEDICINAL USE THEREOF |
| 05/25/2001 | WO2001036641A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 05/25/2001 | WO2001036616A2 Acid nucleic construct bearing a system regulating the expression of a gene |
| 05/25/2001 | WO2001036611A1 Process for the production of a reversibly inactive acidified plasmin composition |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036609A1 Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |